Nuofeng Pharma Series A Financing
Project Overview
On August 23, 2021, Nuofeng Pharma (Chengdu) Co., Ltd. announced the completion of a Series A financing of tens of millions of RMB.
This round was led by DEE Capital and followed by Saiying Capital, with T-Capital acting as the financial advisor for this round.
The proceeds from this financing will be mainly used to accelerate Nuofeng Pharma’s drug research and product development in therapeutic areas such as ophthalmology, anti-tumor, anti-virus, and cardiovascular.
This financing provides capital support for Nuofeng Pharma to further advance the R&D of innovative drugs and high-end formulations, international operations, and product commercialization, and lays the foundation for subsequent product development in China and overseas markets.
Client: Nuofeng Pharma
Nuofeng Pharma is an innovation-driven international pharmaceutical company.
Since its establishment in 2018, the company has adhered to dual operations in China and the United States, and has established a core team with backgrounds from international pharmaceutical companies. Team members come from international pharmaceutical companies such as Roche, Merck, and Teva.
The company’s founder has 25 years of multinational management and entrepreneurial experience in pharmaceutical companies, and has led the approval and launch of multiple NDA and ANDA drugs in the United States.
As of this financing round, Nuofeng Pharma has established more than ten R&D pipelines and is focusing on:
- Ophthalmology
- Anti-tumor
- Anti-virus
- Cardiovascular
Among them, ophthalmology and oncology are the company’s core strategic areas.
Financing Background
Nuofeng Pharma’s business model has obvious international characteristics.
With a strategic direction of “Made in China, Global R&D, Global Market”, the company has laid out R&D and production-related capabilities in Chengdu, China, and New York, USA, and promotes drug R&D, registration, and commercialization through an international team.
Prior to financing, the company already had multiple products in development and was continuously advancing the development of innovative formulations.
Among them, the company’s core blockbuster product plans to enter the US market and carry out in-depth cooperation with international partners.
At this stage of development, the company needs to continuously invest in R&D, registration, production capacity building, and international market expansion. Therefore, capital financing has become an important part of supporting the advancement of the product pipeline and the company’s long-term development.
Financing Plan
This round of financing amounts to tens of millions of RMB.
Investors include:
DEE Capital — Lead Investor
Saiying Capital — Follow-on Investor
T-Capital — Financial Advisor
This round of funding is mainly used for:
- Accelerating ophthalmology product R&D;
- Promoting anti-tumor drug development;
- Promoting anti-viral drug development;
- Promoting product development in the cardiovascular field;
- Supporting the continuous construction of the innovative drug pipeline;
- Promoting the company’s international R&D and commercialization strategy.
Nuofeng Pharma’s International R&D and Industrial Base
Nuofeng Pharma has adopted a dual operation model in China and the United States since its establishment.
The company’s team has rich experience in R&D, registration, and commercialization at international pharmaceutical companies, while also establishing R&D and production capabilities in China.
The company’s production and R&D base in Chengdu Tianfu International Bio-city is planned and constructed in accordance with the relevant standards of the US FDA, EU EMA, and China GMP.
As of this financing round, the company has completed the first phase of construction of approximately 30,000 square meters.
This production and R&D foundation provides an industrial basis for the company’s future promotion of innovative formulation R&D, production, and international market expansion.
Core Technology and Product Layout
Nuofeng Pharma focuses on the fields of high-end formulations and complex formulations.
The company has the LiquiPuls™ patented technology platform and is promoting product development around this technology platform.
The company’s key therapeutic areas include:
Ophthalmology
Ophthalmology is one of Nuofeng Pharma’s core strategic areas, and the company is focusing on the development of high-barrier ophthalmic products.
Oncology
The company continues to lay out anti-tumor drugs and related innovative formulations.
Anti-virus
Antiviral drugs are one of the company’s key R&D directions.
Cardiovascular
The company is also promoting drug research and development in the cardiovascular field.
Through a multi-therapeutic area product pipeline, the company hopes to gradually establish high-end drug R&D and achievement transformation capabilities.
International Commercial Cooperation
While promoting its own R&D and production capacity building, Nuofeng Pharma also actively carries out international industrial cooperation.
At that time, the company was in deep cooperation with Bausch & Lomb and planned to promote its core ophthalmic products to the US market.
This model of “independent R&D + international cooperation + global market” enables the company to combine its own R&D capabilities with the commercialization resources of international partners to promote product internationalization.
For innovative drug companies, international cooperation can not only help products enter overseas markets, but also introduce industrial resources at different stages such as R&D, registration, and commercialization.
Strategic Significance of This Round of Financing
For Nuofeng Pharma, this round of financing is not only a capital supplement, but also an important stage for the company to further move from product R&D to international industrialization.
The financing funds will support the company to further advance the full chain of:
R&D Pipeline → Product Development → Registration Submission → Production Capacity → International Commercialization
For healthcare companies with international strategies, capital financing needs to be matched with the company’s product pipeline, market strategy, and long-term industrial development.
Therefore, healthcare company financing is not just about solving short-term funding needs, but also requires overall planning around the company’s future R&D, registration, commercialization, and capital market development.
T-Capital’s Project Services
In this round of financing, T-Capital acted as the financial advisor to Nuofeng Pharma, participated in the corporate financing process, and provided professional services for the company’s financing strategy and capital matchmaking.
The financing needs of healthcare companies at different stages of development are not the same.
For innovative drug and high-end formulation companies, financing usually needs to consider at the same time:
- Product R&D stage;
- Clinical and registration progress;
- Product pipeline value;
- Technology platform;
- Internationalization strategy;
- Production capacity;
- Commercialization path;
- Investor industrial resources;
- Subsequent financing planning.
Therefore, healthcare financing is not only about capital matchmaking, but also needs to match corporate strategy, asset value, and investor resources.
T-Capital’s Healthcare Financing Services
T-Capital focuses on investment banking services in the broad healthcare field, providing capital transaction services for healthcare companies, including equity financing, M&A, licensing, and strategic cooperation.
Service areas cover:
- New drug R&D
- Medical devices
- Medical diagnostics
- High-value consumables
- Healthcare services
- Biotechnology
- New healthcare technologies
For healthcare companies seeking financing, T-Capital can assist in combing through financing logic, capital needs, and potential investors based on the company’s stage, product pipeline, technology platform, and development strategy.
If Your Company is Looking for Financing
If your company has innovative drugs, medical devices, diagnostic technologies, healthcare services, or other healthcare assets, and is considering:
- A new round of equity financing
- Pre-A / Series A / Series B financing
- Introduction of industrial capital
- Introduction of strategic investors
- License or strategic cooperation
- M&A or equity transactions
- Cross-border capital cooperation
You can communicate with T-Capital about your company’s current development stage and capital needs.
Good healthcare financing is not just about finding funds, but more importantly, about finding capital and industrial resources that match the company’s long-term strategy.
Talk to T-Capital
If you are looking for a professional healthcare investment banking advisor for your next round of financing, you are welcome to contact T-Capital.
Let’s start with your products, technology, pipeline, and development strategy to discuss the appropriate capital path for your company in the next stage.
Learn about T-Capital’s Financing Services
Project Key Information
| Item | Information |
|---|---|
| Company | Nuofeng Pharma (Chengdu) Co., Ltd. |
| Transaction Type | Series A Financing |
| Financing Date | August 23, 2021 |
| Financing Amount | Tens of millions of RMB |
| Lead Investor | DEE Capital |
| Follow-on Investor | Saiying Capital |
| Financial Advisor | T-Capital |
| Core Area | Innovative Drugs, High-end Formulations |
| Key Therapeutic Areas | Ophthalmology, Anti-tumor, Anti-virus, Cardiovascular |
| International Layout | China, United States |
| Core Technology Platform | LiquiPuls™ |
| Use of Proceeds | Drug research and product development |
FAQ
When was Nuofeng Pharma’s Series A financing completed?
Nuofeng Pharma announced the completion of its Series A financing of tens of millions of RMB on August 23, 2021.
Which institutions participated in Nuofeng Pharma’s Series A financing?
This round was led by DEE Capital and followed by Saiying Capital, with T-Capital acting as the financial advisor for this round.
What is the main purpose of Nuofeng Pharma’s Series A financing?
The proceeds from this financing will be mainly used to accelerate the company’s drug development in areas such as ophthalmology, anti-tumor, anti-virus, and cardiovascular.
What role did T-Capital play in this round of financing?
T-Capital acted as the financial advisor for this round of financing, providing financial advisory services to Nuofeng Pharma for this round of financing.
What is Nuofeng Pharma’s main business?
Nuofeng Pharma is an innovation-driven international pharmaceutical company focusing on the R&D of high-end formulations and innovative drugs, mainly in the therapeutic areas of ophthalmology, oncology, anti-virus, and cardiovascular.
What kind of healthcare companies does T-Capital provide financing services for?
T-Capital focuses on investment banking services in the broad healthcare field, with service areas covering new drug R&D, medical devices, medical diagnostics, high-value consumables, healthcare services, and new technologies.
When should a healthcare company seek a financial advisor for financing?
A company can bring in a financial advisor before officially launching financing in order to sort out financing needs, company value, product pipeline, investor profile, and financing strategy earlier, and to establish a targeted capital matchmaking plan.
How to contact T-Capital?
If you are considering equity financing, industrial investment, M&A, licensing, or strategic cooperation for a healthcare company, you can communicate with T-Capital through Contact Us.